Stay updated on L-DOS47 with Vinorelbine/Cisplatin in Lung Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the L-DOS47 with Vinorelbine/Cisplatin in Lung Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the L-DOS47 with Vinorelbine/Cisplatin in Lung Adenocarcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the maximum tolerated dose of L-DOS47 in combination with vinorelbine/cisplatin for treating patients with lung adenocarcinoma in a clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:38:06.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions based on factors like general health condition or prior treatments. This change provides more context and examples of what eligibility criteria entail.
    Difference
    36%
    Check dated 2024-05-22T21:16:54.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:29:53.000Z thumbnail image

Stay in the know with updates to L-DOS47 with Vinorelbine/Cisplatin in Lung Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the L-DOS47 with Vinorelbine/Cisplatin in Lung Adenocarcinoma Clinical Trial page.